FT819 in Subjects With B-cell Malignancies

Study Summary

This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

Conditions

Lymphoma, B-Cell Chronic Lymphocytic Leukemia Precursor B-Cell Acute Lymphoblastic Leukemia

Interventions / Drugs

FT819 Cyclophosphamide Fludarabine IL-2 Bendamustine

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment54 participants

Primary Completion—

Lead SponsorFate Therapeutics

Data Retrieved2026-04-11 04:13:54.903236+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.